Intercept Fades as Goldman Calls NASH Data a Disappointment

(Bloomberg) -- Intercept Pharmaceuticals may be paving the way for what will likely be the first treatment in a potential multi-billion dollar market to treat the fatty liver disease known as NASH,...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.